Clinical trial news

An illustration of multiple hands giving a 'thumbs down' signal.

Genentech will not advance emugrobart (GYM329) into Phase 3 development, after early results from a clinical trial testing it in combination with Evrysdi (risdiplam) in people with spinal muscular atrophy (SMA). According to a letter to the SMA community, this “difficult decision” follows results from the first…

The letters MDA are shown, representing the Muscular Dystrophy Association.

A high-dose regimen of Spinraza (nusinersen) that is up for regulatory approval in the U.S. may help stabilize or improve motor function for people with spinal muscular atrophy (SMA), pooled results from two clinical trials show. “Overall, the improvements observed exceeded what would be expected in a broad…

A headshot, seen close up, shows a woman with black and green hair.

As a licensed clinical social worker based in Amarillo, Texas, Ali Ramos uses her own experience of living with spinal muscular atrophy (SMA) type 2 to create a safe space for her clients to explore their feelings. Her personal journey informs the mental health care and advocacy she…